NBT Bank N A NY Grows Holdings in Thermo Fisher Scientific Inc. $TMO

NBT Bank N A NY lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 10,550 shares of the medical research company’s stock after acquiring an additional 1,004 shares during the period. NBT Bank N A NY’s holdings in Thermo Fisher Scientific were worth $4,891,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock valued at $13,700,154,000 after purchasing an additional 309,207 shares during the last quarter. Norges Bank purchased a new stake in Thermo Fisher Scientific in the second quarter worth approximately $2,264,615,000. Franklin Resources Inc. grew its position in Thermo Fisher Scientific by 11.3% during the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock valued at $1,985,759,000 after acquiring an additional 498,238 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock worth $1,216,612,000 after acquiring an additional 74,971 shares during the last quarter. Finally, Flossbach Von Storch SE boosted its stake in shares of Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after purchasing an additional 1,314,182 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $619.16 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $629.87. The stock has a market cap of $232.62 billion, a P/E ratio of 35.77, a price-to-earnings-growth ratio of 4.11 and a beta of 0.91. The firm’s fifty day simple moving average is $586.34 and its 200 day simple moving average is $523.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the previous year, the firm posted $5.28 EPS. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has initiated a stock buyback plan on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were given a $0.43 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Insider Buying and Selling

In other news, EVP Frederick M. Lowery sold 6,913 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the sale, the executive vice president owned 14,367 shares in the company, valued at approximately $8,586,868.56. The trade was a 32.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 149,271 shares of company stock worth $86,507,282 over the last quarter. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, January 7th. TD Cowen increased their target price on Thermo Fisher Scientific from $654.00 to $696.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Barclays lifted their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price on the stock in a report on Sunday, December 7th. Finally, Citigroup upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and upped their price target for the company from $580.00 to $660.00 in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $625.47.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.